Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer

Published

on

Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer

  • CE marked test for patients with pancreatic ductal adenocarcinoma
  • Prediction of response to first-line gemcitabine-based chemotherapy
  • Developed and validated with real world data and samples

Paris & Montpellier, November 22, 2022 5h45 pm

Eurobio Scientific (Euronext Growth Paris, FR0013240934, ALERS), French leader group in medical diagnosis and life sciences, and Acobiom, a French company expert in the identification of biomarkers and the development molecular diagnostics for precision medicine, announce the signature of an exclusive commercial agreement for the distribution, in France, Germany and the United Kingdom, of GemciTest®, a CE marked test for the predictive diagnostics of response to gemcitabine-based chemotherapy in pancreatic cancer.

A tough cancer without prior assessment of potential treatment efficacy

Pancreatic cancer is an aggressive cancer. According to the International Agency for Research on Cancer (WHO, Globocan data), the incidence of this cancer was about 202,000 new cases in 2020 in Europe and North America, increasing by 2.5% per year on average. In France, this cancer affected about 15,000 patients in 2020, of which nearly 45% would be at the metastatic stage. Diagnosis is generally made by imaging and biological tests on biopsy.

Pancreatic cancer is particularly insidious because it is a “silent” disease that causes no symptoms in its early stages. Often diagnosed at a late stage, this cancer has a poor prognosis. Few treatments are available: surgery and/or chemotherapy. For patients with locally advanced or metastatic cancer at the time of diagnosis, chemotherapy remains the only treatment option, whether it is based on gemcitabine or 5-FU, alone or in combination.

GemciTest®, an in-vitro diagnostic developed by Acobiom, is a predictive PCR test for response to gemcitabine-based chemotherapy in first-line treatment. This CE-marked molecular diagnostic identifies patients with pancreatic ductal adenocarcinoma (PDAC, a form of pancreatic cancer) whose transcriptomic profile is not favorable for the prescription of a first-line gemcitabine-based therapy (alone or in combination). This test will thus make it possible to guide patients towards another more suitable or more effective therapy, to avoid unnecessary side effects or toxicities, and thus to risk a “loss of chance” for these patients.

A new test based on the latest technologies

GemciTest has been developed with Acobiom’s technology platform, which combines genomic and transcriptomic techniques (NGS sequencing, real-time PCR) with bioinformatics, biostatistics and artificial intelligence (machine learning) tools and programs for data processing and analysis.

Developed and validated using real-world data and samples, this molecular diagnostics is based on a proprietary combination of RNA markers present in blood. The test was evaluated in a confirmatory study to measure its sensitivity in predicting the response of PDAC patients to a gemcitabine-based chemotherapy in first-line treatment.

This confirmatory study demonstrated the value of using GemciTest® in clinics and also reveals the potential of RNA marker combinations in blood in the development of precision medicine and personalized therapy for patients with pancreatic cancer.

“The signature of this commercial agreement with Eurobio Scientific is the recognition of the quality of the developments made by the Acobiom team by a key-player of the in-vitro diagnostic industry in France”, says Didier Ritter, President of Acobiom. “It is also a first step for our company, as other predictive diagnostics in precision medicine are currently in development, notably to predict the response to 5-FU-based chemotherapy in first-line treatment of pancreatic cancer.”

Jean-Michel Carle, CEO of Eurobio Scientific, added: “The importance of a predictive response test for a disease as difficult as pancreatic cancer will be a major asset for physicians by allowing their patients to avoid losing chances due to inappropriate treatments. The strength of the new technologies used and the quality of the work done by Acobiom, as demonstrated by the results of their real-world clinical tests, have convinced us of the immediate relevance of this new test“.

About GemciTest®

GemciTest® is a predictive molecular diagnostic for response to gemcitabine-based chemotherapy in first-line treatment. This CE-marked PCR test is intended for patients with pancreatic ductal adenocarcinoma (PDAC). This in-vitro diagnostic has been developed from Acobiom’s technology platform, which combines genomic and transcriptomic techniques (NGS sequencing, real-time PCR) on the one hand, and bioinformatics, biostatistics and machine learning tools and programs for data processing and analysis on the other.
Developed and validated using real world data and samples, GemciTest® is based on a patented combination of RNA markers present in blood and has been evaluated in a confirmatory study. The clinical validation of this PCR test was performed on 336 patients (mean age 68.7; 37-88). Patients with a clinical benefit (OS > 8.7 months; PFS ≥3.5 months) identified by GemciTest® (29.7%) had significantly a longer PFS (5.3 vs. 2.8 months) and a longer OS (10.4 vs. 4.8 months). GemciTest® -positive patients had significantly longer PFS (HR=0.53 (95% CI: 0.31-0.92); p=0.023) and OS (HR=0.49 (95% CI: 0.29-0.85); p=0.0091).

About Eurobio Scientific

Eurobio Scientific is a major player in the field of specialty in vitro diagnostics. It is active in the research and marketing of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and provides dedicated reagents to research laboratories, including pharmaceutical and biotechnology companies. With its numerous partnerships and strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary molecular biology products. The Group has approximately 250 employees, four manufacturing facilities based in the Paris area, Germany, the Netherlands and the USA, and subsidiaries in Dorking in the UK, Sissach in Switzerland, Bünde in Germany and Utrecht in the Netherlands.

For more information, please visit the website: www.eurobio-scientific.com

Eurobio Scientific shares are listed on Euronext Growth Paris.
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech Indices, label Euronext European Rising Tech
Mnémonics: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

About Acobiom

Acobiom is a biotechnology company specializing in the discovery of biological markers (biomarkers) and the development of innovative molecular diagnostics for applications in personalized medicine or precision medicine. Precision medicine aims at personalizing treatments according to certain biomarkers in order to obtain a better therapeutic effectiveness, to limit the side effects of a treatment and to ensure a better quality of life for the patient. The diagnostics developed by ACOBIOM respond to these needs and support medical teams in choosing the most effective treatment best suited to the transcriptomic profile of each patient. These diagnostics are developed from biomarkers, identified by the company’s scientific team, which has more than 20 years of expertise in the study of gene expression and a technological platform combining genomics, transcriptomics, bioinformatics, biostatistics (data science) and machine learning (artificial intelligence). Founded in 1999, Acobiom is located in the Euromedicine Biopole in Montpellier (France), and is a member of the regional health clusters.
For more information: www.acobiom.com

Media and investor Contacts

        Eurobio Scientific         Calyptus
        Jean-Michel Carle, CEO         Mathieu Calleux / Maisie Mouret
        Denis Fortier, Managing director        Tel.: +33 1 53 65 68 68 – [email protected]
        Tel.: +33 1 69 79 64 80         

        Acobiom
        Philippe Outrebon
        [email protected]

Attachment

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

$10 million Artificial Intelligence Mathematical Olympiad Prize appoints further advisory committee members

Published

on

$10-million-artificial-intelligence-mathematical-olympiad-prize-appoints-further-advisory-committee-members

D. Sculley, Kevin Buzzard, Leo de Moura, Lester Mackey and Peter J. Liu appointed to the advisory committee for the Artificial Intelligence Mathematical Olympiad Prize.
LONDON, April 26, 2024 /PRNewswire/ — XTX Markets’ newly created Artificial Intelligence Mathematical Olympiad Prize (‘AIMO Prize’) is a $10mn challenge fund designed to spur the creation of a publicly shared AI model capable of winning a gold medal in the International Mathematical Olympiad (IMO).

XTX Markets is delighted to announce the appointment of five further advisory committee members. This group brings great expertise in machine learning, including D. Sculley, the CEO of Kaggle; Lester Mackey, a Principal Researcher at Microsoft Research and a Macarthur Fellow; and Peter J. Liu, a research scientist at Google DeepMind.
Prolific mathematicians Kevin Buzzard, who achieved a perfect score in the International Mathematical Olympiad, and Leo De Moura who is the Chief Architect for Lean, the automated reasoning tool, also join the advisory group.
They join the existing advisory committee members Terence Tao and Timothy Gowers, both winners of the Fields Medal, as well as Dan Roberts, Geoff Smith and Po-Shen Loh.
The AIMO Advisory Committee will support the development of the AIMO Prize, including advising on appropriate protocols and technical aspects, and designing the various competitions and prizes.
Simon Coyle, Head of Philanthropy at XTX Markets, commented:
“We are thrilled to complete the AIMO Advisory Committee with the appointments of D., Kevin, Leo, Lester and Peter. Together, they have enormous experience in machine learning and automated reasoning and are already bringing expertise and wisdom to the AIMO Prize. We look forward to announcing the winners of the AIMO’s first Progress Prize soon, and then publicly sharing the AI models to support the open and collaborative development of AI.”
Further information on the AIMO Prize
There will be a grand prize of $5mn for the first publicly shared AI model to enter an AIMO approved competition and perform at a standard equivalent to a gold medal in the IMO. There will also be a series of progress prizes, totalling up to $5mn, for publicly shared AI models that achieve key milestones towards the grand prize.
The first AIMO approved competition opened to participants in April 2024 on the Kaggle competition platform. The first progress prize focuses on problems pitched at junior and high-school level maths competitions. There is a total prize pot of $1.048m for the first progress prize, of which at least $254k will be awarded in July 2024, There will be a presentation of progress held in Bath, England in July 2024, as part of the 65th IMO.
For more information on the AIMO Prize visit: https://aimoprize.com/ or the competition page on Kaggle: https://www.kaggle.com/competitions/ai-mathematical-olympiad-prize/
Advisory Committee member profiles:
D. Sculley
D. is the CEO at Kaggle. Prior to joining Kaggle, he was a director at Google Brain, leading research teams working on robust, responsible, reliable and efficient ML and AI. In his career in ML, he has worked on nearly every aspect of machine learning, and has led both product and research teams including those on some of the most challenging business problems. Some of his well-known work involves ML technical debt, ML education, ML robustness, production-critical ML, and ML for scientific applications such as protein design.
Kevin Buzzard
Kevin a professor of pure mathematics at Imperial College London, specialising in algebraic number theory. As well as his research and teaching, he has a wide range of interests, including being Deputy Head of Pure Mathematics, Co-Director of a CDT and the department’s outreach champion. He is currently focusing on formal proof verification, including being an active participant in the Lean community. From October 2024, he will be leading a project to formalise a 21st century proof of Fermat’s Last Theorem. Before joining Imperial, some 20 years ago, he was a Junior Research Fellow at the University of Cambridge, where he had previously been named ‘Senior Wrangler’ (the highest scoring undergraduate mathematician). He was also a participant in the International Mathematical Olympiad, winning gold with a perfect score in 1987. He has been a visitor at the IAS in Princeton, a visiting lecturer at Harvard, has won several prizes both for research and teaching, and has given lectures all over the world.
Leo de Moura
Leo is a Senior Principal Applied Scientist in the Automated Reasoning Group at AWS. In his spare time, he dedicates himself to serving as the Chief Architect of the Lean FRO, a non-profit organization that he proudly co-founded alongside Sebastian Ullrich. He is also honoured to hold a position on the Board of Directors at the Lean FRO, where he actively contributes to its growth and development. Before joining AWS in 2023, he was a Senior Principal Researcher in the RiSE group at Microsoft Research, where he worked for 17 years starting in 2006. Prior to that, he worked as a Computer Scientist at SRI International. His research areas are automated reasoning, theorem proving, decision procedures, SAT and SMT. He is the main architect of several automated reasoning tools: Lean, Z3, Yices 1.0 and SAL. Leo’s work in automated reasoning has been acknowledged with a series of prestigious awards, including the CAV, Haifa, and Herbrand awards, as well as the Programming Languages Software Award by the ACM. Leo’s work has also been reported in the New York Times and many popular science magazines such as Wired, Quanta, and Nature News.
Lester Mackey
Lester Mackey is a Principal Researcher at Microsoft Research, where he develops machine learning methods, models, and theory for large-scale learning tasks driven by applications from climate forecasting, healthcare, and the social good. Lester moved to Microsoft from Stanford University, where he was an assistant professor of Statistics and, by courtesy, of Computer Science. He earned his PhD in Computer Science and MA in Statistics from UC Berkeley and his BSE in Computer Science from Princeton University. He co-organized the second place team in the Netflix Prize competition for collaborative filtering; won the Prize4Life ALS disease progression prediction challenge; won prizes for temperature and precipitation forecasting in the yearlong real-time Subseasonal Climate Forecast Rodeo; and received best paper, outstanding paper, and best student paper awards from the ACM Conference on Programming Language Design and Implementation, the Conference on Neural Information Processing Systems, and the International Conference on Machine Learning. He is a 2023 MacArthur Fellow, a Fellow of the Institute of Mathematical Statistics, an elected member of the COPSS Leadership Academy, and the recipient of the 2023 Ethel Newbold Prize.
Peter J. Liu
Peter J. Liu is a Research Scientist at Google DeepMind in the San Francisco Bay area, doing machine learning research with a specialisation in language models since 2015 starting in the Google Brain team. He has published and served as area chair in top machine learning and NLP conferences such as ICLR, ICML, NEURIPS, ACL and EMNLP. He also has extensive production experience, including launching the first deep learning model for Gmail Anti-Spam, and using neural network models to detect financial fraud for top banks. He has degrees in Mathematics and Computer Science from the University of Toronto.
About XTX Markets:
XTX Markets is a leading financial technology firm which partners with counterparties, exchanges and e-trading venues globally to provide liquidity in the Equity, FX, Fixed Income and Commodity markets. XTX has over 200 employees based in London, Paris, New York, Mumbai, Yerevan and Singapore. XTX is consistently a top 5 liquidity provider globally in FX (Euromoney 2018-present) and is also the largest European equities (systematic internaliser) liquidity provider (Rosenblatt FY: 2020-2023).
The company’s corporate philanthropy focuses on STEM education and maximum impact giving (alongside an employee matching programme). Since 2017, XTX has donated over £100mn to charities and good causes, establishing it as a major donor in the UK and globally.
In a changing world XTX Markets is at the forefront of making financial markets fairer and more efficient for all.
 

View original content:https://www.prnewswire.co.uk/news-releases/10-million-artificial-intelligence-mathematical-olympiad-prize-appoints-further-advisory-committee-members-302128542.html

Continue Reading

Artificial Intelligence

Hikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024

Published

on

hikvision-redefines-urban-mobility-with-aiot-powered-solutions-at-intertraffic-2024

HANGZHOU, China, April 26, 2024 /PRNewswire/ — Hikvision made a significant appearance at Intertraffic Amsterdam, the leading global trade fair for mobility and traffic technology. At the trade event, Hikvision unveiled a suite of traffic, transport, and parking management solutions and products powered by Artificial Intelligence of Things (AIoT) technology, which promised to improve urban mobility, road safety, and operational efficacy.

Elevating urban traffic intelligence with AIoT
One highlight of the Hikvision stand was its intelligent urban traffic solution, which leveraged the power of AIoT to deliver comprehensive real-time monitoring, incident detection, and traffic control. This solution intelligently reshapes traffic dynamics, offering a more responsive and data-driven approach to enhance situational awareness and traffic management. Key innovations in the solution included:
Hikvision’s radar-video fusion camerasThese combine the range perception of radar with the visual perception of video. The 4 MP Radar and Video Vehicle Detector, for example, helps to enhance road safety by providing early warning of potential hazards in challenging situations such as blind spots at intersections and obstacles outside the visual range.Hikvision’s All-In-One Traffic SpotterThis stands out with its multifaceted design incorporating video, radar, and lighting technologies for heightened traffic violation detection. Its streamlined column design facilitates effortless installation.Hikvision’s Radar-Linked PTZ Camera This ensures consistent performance in adverse weather and lightening conditions, and minimizes false alarms with advanced deep-learning algorithms.Innovating parking management
Hikvision also introduced its parking management solutions. These combine extremely precise license plate recognition and intelligent barrier controls incorporating highly accurate radar sensors. This comprehensive approach enhances security, reduces the need for manual intervention, and streamlines traffic flow across parking areas. The Global Shutter CMOS* (GMOS) ANPR camera was a new addition to the lineup. Designed to seamlessly blend in the environment, it is tailored for the task of discreetly capturing license plates at parking facilities that prioritize subtlety.
Advancing public transportation safety and efficiency
Attendees also had the opportunity to explore Hikvision’s latest public transport solutions, integrating AI-driven analytics with advanced video security, on-site voice broadcasting, and centralized management for enhanced onboard security, improved passenger experience, and operational efficiency for buses and taxis. This included the Four-way monitoring system and the Panoramic Auxiliary System, both designed to reduce blind spots and provide high-definition imaging to improve driving safety.
“As ever, we are continually expanding our suite of technologies to enhance traffic safety and efficiency,” said Nick Wu, Project Product Director at Hikvision Europe. “Our commitment lies in minimizing the need for extensive roadside installations by incorporating comprehensive perception and robust AI within unified device frameworks. These innovations automate and streamline every aspect of traffic management, from violation detection to traffic flow monitoring, driving safety, and parking management.”
To find out more about Hikvision’s urban mobility products and solutions, please explore its official website.
Note: CMOS stands for Complementary Metal-Oxide-Semiconductor.
Photo – https://mma.prnewswire.com/media/2398456/Hikvision_redefines_urban_mobility_AIoT_powered_solutions_Intertraffic_2024.jpgPhoto – https://mma.prnewswire.com/media/2398459/Hikvision_redefines_urban_mobility_AIoT_powered_solutions_Intertraffic_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/hikvision-redefines-urban-mobility-with-aiot-powered-solutions-at-intertraffic-2024-302128527.html

Continue Reading

Artificial Intelligence

London Blockchain Conference Launches the No Future Campaign

Published

on

london-blockchain-conference-launches-the-no-future-campaign

LONDON, April 26, 2024 /PRNewswire/ — The London Blockchain Conference is excited to announce the launch of its ground-breaking, ‘No Future Campaign’. This initiative aims to create a strong narrative surrounding blockchain technology by challenging perceptions and sparking conversations. By creating this platform, the campaign aims to instil a fear of missing out (FOMO) sensation among the audience, positioning the London Blockchain Conference as a gateway to securing a stake in the future and unlocking the potential of blockchain technology.

With a bold and evocative narrative theme, the campaign will initially confront the audience with a jarring reality check of “NO FUTURE” and then resolve the statement “WITHOUT BLOCKCHAIN” to spark curiosity and engagement with the optimistic revelation that blockchain holds the key to a prosperous future.
The ‘No Future Campaign’ started on 17 April 2024 with the London Blockchain Conference creating and executing content on/with media platforms and partnerships:
Wharf Life inserts (17/04/2024) – Print and a digital advert/editorial-sponsored pieces.Animations being released on paid and organic channels in a 3-week campaign.Alex Stein, Conference Director said, “The No Future Campaign is a call for individuals, enterprises, and governments to recognise the importance and role of blockchain in shaping the future. Through the London Blockchain Conference, we aim to educate and inspire attendees to understand and harness the potential of blockchain technology.”
The three-day London Blockchain Conference at the ExCel will bring together politicians, business leaders, and innovators. The conference will be running from 21 – 23 May 2024 and will focus on disruptive and real-world applications of blockchain technology and the impact it is having on politics, emerging technologies, and enterprises.
For more information about the ‘No Future campaign’, visit the London Blockchain Conference website.
About the London Blockchain Conference
NETWORK. LEARN. ENGAGE. 
 At the London Blockchain Conference, we show how Blockchain will change the world and help people see another way to manage data, build scalable on-chain solutions and achieve great things. We do this by creating valuable, insightful, and engaging events that educate and inform, allowing you to connect and network to build strong business relationships. Our conference is the best avenue to see blockchain innovations, ecosystem announcements, product launches, technology updates, keynote speeches, panels, and fireside chats from blockchain leaders. Join us and experience it for yourself. 
 
 

View original content:https://www.prnewswire.co.uk/news-releases/london-blockchain-conference-launches-the-no-future-campaign-302128526.html

Continue Reading

Trending